An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
Trial details
- Registry ID
- NCT04988867
- Phase
- Phase 2, Phase 3
The FDA approved Trofinetide on 10 Mar 2023.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett SyndromeNCT04988867 | ACAD | Phase 2, Phase 3 | Terminated | 2023-05-31Actual |
| Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromeNCT04279314 | ACAD | Phase 3 | Completed | 2022-08-19Actual |
| Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)NCT04181723 | ACAD | Phase 3 | Completed | 2021-10-28Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2023-03-10Day | Trofinetide | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA217026", "applicant_as_listed_by_fda": "ACADIA PHARMS INC", "brand_names": ["DAYBUE"], "active_ingredients": ["TROFINETIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230310", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |